Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
L. Dousset(Centre Hospitalier Universitaire de Bordeaux), Julien Sénéschal(Université de Bordeaux), Nicolas Andreu(Hôpital Saint-André), Katia Boniface(Université de Bordeaux), Marie Kostine(Hôpital Cardiologique du Haut-Lévêque), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), M. Beylot‐Barry, Thomas Barnetche(Université de Bordeaux), E. Gérard(Université de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), A. Pacaud(Hôpital Saint-André), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 27
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k